Physician profile
David Y Rhee
NPI 1417177569
$2,332.20
in general payments reported to CMS, 2019-2025
18 companies · $357 in 2025
The $357 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $74.26 · 2021: $199 · 2022: $271 · 2023: $428 · 2024: $603 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,388.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $676.99 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $598.18 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $393.61 | 2023-2025 | Syfovre |
| Abbvie INC. | $152.46 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $119.32 | 2019 | |
| Alcon Vision LLC | $106.49 | 2022 | |
| Allergan, INC. | $103.18 | 2019-2021 | |
| Sandoz INC. | $36.15 | 2024 | Cimerli |
| Coherus Oncology, INC. | $35.95 | 2023 | |
| Mallinckrodt Enterprises LLC | $28.11 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.73 | 2021 | |
| Astellas Pharma US INC | $22.42 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.35 | 2019 | |
| Biogen, INC. | $14.26 | 2023 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rhee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.